Jerini Announces Research Collaboration Between Jerini Ophthalmic and UCL Institute of Ophthalmology Investigating New Treatments for AMD
07 déc. 2007 05h37 HE
|
Jerini AG
BERLIN, Dec. 7, 2007 (PRIME NEWSWIRE) -- Jerini AG (Frankfurt:JI4) announced today that Jerini Ophthalmic, Inc., its wholly-owned U.S. subsidiary, signed a research collaboration agreement with...
Jerini Reports Financial Results for First Nine Months of 2007
14 nov. 2007 03h18 HE
|
Jerini AG
BERLIN, Nov. 14, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) reported financial results according to International Financial Reporting Standards (IFRS) for the first nine months ended September 30,...
Jerini Submits New Drug Application for Icatibant in the Treatment of HAE to the FDA and Requests Priority Review
29 oct. 2007 06h35 HE
|
Jerini AG
BERLIN, Oct. 29, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today the submission of its electronic New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema (HAE)...
Jerini Ophthalmic Treats First Patient in Phase I Trial for Age-related Macular Degeneration
09 oct. 2007 03h11 HE
|
Jerini AG
BERLIN, Oct. 9, 2007 (PRIME NEWSWIRE) -- Jerini AG (Frankfurt:JI4) announced today that its wholly-owned subsidiary, Jerini Ophthalmic, Inc., has treated the first patient in its Phase I clinical...
Jerini Initiates FDA Submission Process of New Drug Application For Icatibant in the Treatment of HAE
08 oct. 2007 04h45 HE
|
Jerini AG
BERLIN, Oct. 8, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that the complete New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema (HAE) has been sent to...
Jerini Regains Commercialization Rights to Icatibant for the Treatment of Hereditary Angioedema in North America
04 sept. 2007 07h40 HE
|
Jerini AG
BERLIN, Sept. 4, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today the termination of the license agreement between its affiliate, Jerini US, Inc., and Kos Life Sciences, Inc. for the...
Jerini Receives EMEA Filing Acceptance of Its Marketing Application for Icatibant in the Treatment of Hereditary Angioedema
16 août 2007 09h23 HE
|
Jerini AG
BERLIN, Aug. 16, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today the acceptance of its Marketing Authorization Application (MAA) by the European Medicines Evaluation Agency (EMEA) on...
Jerini AG Reports First Half Financial Results for 2007
14 août 2007 03h13 HE
|
Jerini AG
-- Submission of European Marketing Authorization Application
completed
-- Accelerated Assessment granted by EMEA for expedited review
-- Completion of U.S. filing with FDA expected in third...
FDA Accepts Jerini Ophthalmic's IND of JSM 6427 For the Treatment of AMD
13 juil. 2007 03h51 HE
|
Jerini AG
BERLIN, July 13, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that the U.S. Food and Drug Administration (FDA) accepted the Investigative New Drug (IND) application submitted by...
Jerini AG Reports First Quarter Financial Results
15 mai 2007 03h22 HE
|
Jerini AG
BERLIN, May 15, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) reported financial results for the first quarter ended March 31, 2007. Under International Financial Reporting Standards (IFRS), revenues...